Talazoparib plus enzalutamide showed improved radiographic progression-free survival (rPFS) compared to placebo plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
The most common treatment-emergent adverse events observed in the talazoparib group were anaemia, neutropenia, and fatigue, with anaemia being the most common grade 3-4 event.

Image courtesy of interviewee